Among pediatric and adult patients with cystic fibrosis, the average number of chronic respiratory therapies used fell after ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Fibrosis in multiple organs is a prominent pathological finding and distinguishing hallmark of systemic sclerosis (SSc). Findings during the past 5 years have contributed to a more complete ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

Pulmonary exacerbations are common in children with cystic fibrosis during the first 3 years of life and are associated with ...

Intestinal fibrosis is a common and potentially serious complication of IBD that results from the reaction of intestinal tissue to the damage inflicted by chronic inflammation. The traditional view ...

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...

People in Lexington got a chance to experience an elaborate holiday display Sunday while supporting a good cause.

On October 3, 2025, a multicenter team from Shenzhen University, Xiangya Hospital of Central South University, Zhujiang Hospital of Southern Medical University, Wuxi People's Hospital Affiliated to ...